BIBLIOGRAFIA
Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesys induced by anticancer therapy. Trends Pharmacol Sci 1988; 9:334-341.
Andrews PLR and Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993; 29A (Suppl 1):511-516.
Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-HT signalling in patients with constipation- and diarrhoea-predominant irritable bowel syndrome. Gastroenterology 2006; 130:34-43.
Bellini M et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am. J. Gastroenterol 2003; 98:2705–2711.
Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 1998; 44(3):169-178. Bradley CC and Blakely RD. Alternative splicing of the human serotonin transporter gene. J. Neurochem. 1997; 69:1356–1367.
Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120:652-668.
Camilleri M. Pharmacogenomics and serotoninergic agents: research observations and potential clinical practice implications. Neurogastroenterol Motil 2007; 19 (Suppl. 2):40-45.
Camilleri M, Atanasova E, Carlson PJ et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhoea-predominant IBS. Gastroenterology 2002; 123:425-432.
Camilleri M. Is there a SERT-ain association with IBS? Gut 2004; 53:1396-1399.
Chaudhary NA and Truelove SC. The irritable colon syndrome. Q J Med 1962; 123:307–322.389.
Chen J, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, Gershon MD. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21:6348–6361.
Chen J, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea-pig 5-HT transporter: cloning, expression, distribution and function in intestinal sensory reception. Am J Physiol 1998; 275:433-448.
Coates MD, Johnson AC, Greenwood-Van Meerveld B, Mawe GM. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 2006; 18:464-471.
Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122:2078-2080.
Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del Tacca M. The genetics of the serotonin transporter and irritable bowel syndrome. Trends in Molecular Medicine-491 2008; 14:295-304.
Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and gastrointestinal disorders. Dis Colon Rectum 2006; 50:376-388.
Delbruck SJ, Wendel B, Grunewald I, Sander I, Morris-Rosendahl D, Crocq MA, Berrettini WH, Hoehe MR. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet Cell Genet 1997; 79:214-220.
De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61:317-332.
Drossman DA, Creed FH, Olden KW et al. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999; 45 (Suppl.2): II 25-II 30.
Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 2000; 105:1555–1562
Esmaili A, Nazir SF, Borthakur A, Yu D, Turner JR, Saksena S, Singla A, Hecht GA, Alrefai WA, Gill RK. Enteropathogenic E.Coli infection inhibits intestinal serotonin transporter (SERT) function and expression. Gastroenterology 2009.
Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002; 51 (Suppl. 1):i91–5.
Fiskerstrand CE et al. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embrionic stem cells. FEBS Lett. 1999; 458:171–174.
Flattem NL and Blakely RD. Modified structure of the human serotonin transporter promoter. Mol. Psychiatry 2000; 5:110–115.
Fozard JR. B Jones, FD King, OJ Sanger. Role of 5-HT3 receptors in
nociception. 5-HT3 Receptor Antagonists CRC Inc, Boca Raton, FL 1993; pp 241-253.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997 Apr; 11:395-402.
Frisch A et al. A rare short allele of the serotonin transporter promoter region (5-HTTLPR) found in an aggressive schizophrenic patient of Jewish Libyan origin. Psychiatr. Genet. 2000; 10:179–183.
Fukudo S, Kanazawa M, Mizuno T, Hamaguchi T, Kano M, Watanabe S, Sagami Y, Shoji T, Endo Y, Hongo M, Itoyama Y, Yanai K, Tashiro M, Aoki M. Impact of Serotonin Transporter Gene Polymorphism on Brain Activation by Colorectal Distention. NeuroImage 2009.
Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Reviews in Gastroenterological Disorders 2003; 3 (Suppl.2): S25-S34.
Gershon MD and Tack J. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007 Jan; 132:397-414.
Gill RK, Pant N, Saksena S, Singla A, Nazir TM, Vohwinkel L, Turner JR, Goldstein J, Alrefai WA, Dudeja PK. Function, expression and characterization of the serotonin transporter (SERT) in the native human intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294:G254–G262.
Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. Current Therapeutic Research 1999; 12:696-702.
Givens RC and Watkins PB. Pharmacogenetics and clinical gastroenterology. Gastroenterology 2003; 12:240-248.
Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR, Raybould HE. Expression of 5-HT3 receptors in the rat gastrointestinal tract. Gastroenterology 2002; 123:217–226.
Gunn MC, Cavin AA, Mansfield JC. Management of irritable bowel syndrome. Postgrad Med J 2003; 79:154-158.
Gwee KA et al. The role of psychological and biological factors in postinfective gut disfunction. Gut 1999; 44:400-406.
Hamon M, Lanfumey LEL, Mestikawi S, Boni C, Miquel MC, Bolanos F, Schechter L, Gozlan H. The main features of central 5-HT1 receptors.
Neuropsychopharmacol 1990; 3:349-360.
Hansen MB and Witte AB. The role of serotonin in intestinal luminal sensing and secretion. Acta Physiologica 2008; 193:311-323. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621-2624.
Heils A, Mossner R, Lesch KP. The human serotonin transporter gene polymorphism-basic research and clinical implications. J Neural Transm 1997; 104(10):1005-1014.
Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-HT concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 2003; 52:663-670.
Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997; 36:419–428. Hu XZ et al. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol. Clin. Exp. Res. 2005; 29:8–16.
Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive– compulsive disorder. Am. J. Hum. Genet. 2006; 78:815–826.
Inoue T, Kusumi I, Yoshioka M. Serotonin transporters. Curr Drug Target CNS Neurol Disord 2002; 1:519-529.
Kalin NH, Shelton SE, Fox AS, Rogers J, Oakes TR, Davidson RJ. The serotonin transporter genotype is associated with intermediate brain phenotypes that depend on the context of eliciting stressor. Mol. Psychiatry 2008.
Kharkevich DA, Churukanov VV. Pharmacological regulation of descending cortical control of the nociceptive processing. Eur J Pharmacol 1999; 375:121– 31.
Kenny B, Finlay BB. Intimin-dependent binding of enteropathogenic Escherichia coli to host cells triggers novel signaling events, including tyrosine phosphorylation of phospholipase C-gamma1. Infect Immun 1997;65:2528-36. Kilic F, Murphy DL, Rudnick G. A human serotonin transporter mutation
Kim DY and Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95:2698-2709.
Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D, McKinzie S, Zinsmeister AR, Urrutia R. Association of distinct alfa-2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53:829-837.
Kim DY, Tolliver TJ, Huang SJ, Martin BJ, Andrews AM, Wichems C, Holmes A, Lesch KP, Murphy DL. Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 2005; 49:798–810.
Kohen R, Jarret ME, Cain KC, Jun S-E, Navaja GP, Symonds S, Heitkemper MM. The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome. Springer Science+Business Media, LLC 2008.
Kremer I, Bachner-Melman R, Reshef A, Broude L, Nemanov L, Gritsenko I, Heresco-Levy U, Elizur Y, Ebstein RP. Association of the Serotonin Transporter Gene With Smoking Behavior. Am J Psychiatry 2005; 162:924-930.
Kunugi H et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 1997; 2:457–462.
Kunze WA and Furness JB. The enteric nervous system and regulation of intestinal motility. Ann Rev Physiol 1999; 61:117-142.
Lea R and Whorwell PJ. New insights into the psychosocial aspects of irritable bowel syndrome. Current Gastroenterology Reports 2003; 5:343-350.
Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz DL, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM. Pharmacogenetics of membrane transporters investigators. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100(10):5896-5901.
Lee DY, Park H, Kim WH, Lee SI, Seo YJ, Choi YC. Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome. Korean J Gastroenterol 2004; 43:18-22.
Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. International Journal of Neuropsychopharmacology 2002; 5:255-275.
Lesch KP, Wolozin BL, Murphy DL et al. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60:2319-2322.
Lesch KP and Moessner R. Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 1998; 44:179-192.
Li Q. Cellular and molecular alterations in mice with deficient and reduced serotonin transporters. Mol. Neurobiol. 2006; 34:51–66.
Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J. Neurochem. 2003; 84:1256–1265.
Li Q, Nie Y, Xie J, Tang W, Liang P, Sha W, Yang H, Zhou Y. The association of serotonin transporter genetic polymorphism and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007; 52:2942-2949.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 Apr; 130:1480-1491. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993; 34:229-234.
Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 2004; 140:169–181.
Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107:271-293.
Meier Y et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos. 2007; 35:590–594.
Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109:40-52.
Michaelovsky E, Frisch A, Rockah R, Peleg L, Magal N, Shohat M, Weizman R. A novel allele in the promoter region of the human serotonin transporter gene. Mol. Psychiatry 1999; 4(1):97-99.
genetic disorders and pharmacogenetics. Mol Intervetions 2004; 4(2):109-123. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM, Holmes A, Lesch KP, Wendland JR. How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008; 55:932-960.
Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5(1):32-38.
Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients. BMJ 1997; 314:779-782. Niesler B, Kapeller J, Fell C, Atkinson W, Möller D, Fischer C, Whorwell P, Houghton LA. 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene and irritable bowel syndrome: effect of bowel habit and sex. European Journal of Gastroenterology & Hepatology 2009; 00:000-000.
Ohman L and Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007 Mar; 39(3):201-215.
Olivier B, Soudijn W, Van Wijngaarden I. Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res 2000; 54:59-119.
Ozsarac N et al. Alternative non-coding exons support serotonin transporter mRNA expression in the brain and gut. J. Neurochem. 2002; 82:336–344.
Pae CU, Masand PS, Ajwani N, Lee C, Patkar AA. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 2007; 61:1708-1718.
Park JM, Choi MG, Park JA, Oh JH, Cho YK, Lee IS, Kim SW, Choi KY, Chung IS. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil 2006; 18:995-1000.
Pata C, Erdal ME, Derici E et al. Serotonin transporter gene polymorphism in IBS. Am J Gastroenterol 2002; 97:1780-1784.
Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy S, Shelton RC, Hewlett WA, Sutcliffe JS, Blakely RD. Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 2005; 102:11545–11550.
Racke K, Reimann A, Schworer H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 1996; 73(1-2):83-87.
Rasmussen HB and Werge TM. Novel procedure for genotyping of the human serotonin transporter gene-linked polymorphic region (5-HTTLPR) – a region with a high level of allele diversity. Psychiatr. Genet. 2007; 17:287–291.
Saito YA, Locke GR III, Zimmerman JM, Holtmann G, Slusser JP, De Andrade M, Petersen GM, Talley NJ. A genetic association study of 5-HTTLPR and GN3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19:465-470.
Sandler RS, Everhart JE, Donowitz M. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500-1511.
Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14(3):221-227.
Schwetz I, Bradesi S, Mayer EA. The pathophysiology of irritable bowel syndrome. Minerva med 2004; 95:419-426.
Sikander A, Rana SV, Sinha SK, Prasad KK, Arora SK, Sharma SK, Singh K. Serotonin Transporter Promoter Variant Analisys in Indian IBS Patients and Control Population. J Clin Gastroenterol 2009; 00:000-000.
Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlung J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97:389-396.
Smits KM, Smits LJM, Schouten JSAG, Stelma FF, Nelemans P, Prins MH. Influence of SERTLPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9:433-441.
Spiller R. Clinical update: irritable bowel syndrome. Lancet 2007; 369:1586-1588.
Strigo IA, Simmons AN, Matthews SC, Craig A.D, Paulus MP. Association of major depressive disorder with altered functional brain response during anticipation and processing of heat pain. Arch Gen Psychiatry 2008; 65:1275-1284.
Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, Li C, Folstein SE, Blakely RD. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am. J.
Takeshi I, Ichiro K, Itsuhiro T. Serotonin transporters. Current Drug Targets-CNS Neurological Disorders 2002; 1:519-529.
Tam FSF, Hiller K, Bunce K. Investigation of the 5-HT receptor type involved in inhibition of spontaneous activity of human colonic circular muscle. Br J Pharmacol 1992; 106:25P.
Tjurmina OA, Armando I, Saavedra JM, Goldstein DS, Murphy DL. Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 2002; 143:4520–4526. Tjurmina OA, Armando I, Saavedra JM, Li Q, Murphy DL. Life-long serotonin reuptake deficiency results in complex alterations in adrenomedullary responses to stress. Ann. N. Y. Acad. Sci. 2004; 1018:99–104.
Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 2005; 17:637-642.
Vanhoenacker P, Haegeman G, Leysen JE. 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol Sci 2000; 21:70–77.
Van Kerkhoven LAS, Laheij RJF, Jansen BMJ. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:979-986.
Van Lelyveld N et al. Regional differences in expression of TPH-1, SERT, 5-HT3 and 5-HT4 receptors in the human stomach and duodenum. Neurogastroenterol. Motil. 2007; 19:342–348.
Wang BM, Wang YM, Zhang WM, Zhang QY, Liu WT, Jiang K, Zhang J. Serotonin transporter gene polymorphism in irritable bowel syndrome: a double-blind randomized-controlled study. Zhongua Nei Ke Za Zhi 2004; 43:439-441. Wendland JR et al. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol. Psychiatry 2006; 11:224–226.
Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102:2767-2776.
Wilkie MJV, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The Pharmacogenomics Journal 2009; 9:61–70.
Wood JD, Alpers DH, Andrews PL. Fundamentals of neurogastroenterology. Gut 1999; 45 (Suppl. 2), II6–II16.
Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, Knaggs A, Asquith S, Taylor I, Bahari B, Crocker N, Rallan R, Varsani S, Montgomery D, Alpers DH, Dukes GE, Purvis I, Hicks GA. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53:1452-1458.
